InDex Pharmaceuticals has announced that the evaluation of alternatives for the company’s future has been finalized and presented to the Board according to plan.
A step-wise approach was adopted to narrow down the number of options. The evaluation was conducted with support from an external financial advisor with the aim to maximize shareholder value.
The Board has decided to proceed with the recommended reverse merger.”
The Board has decided to proceed with the recommended reverse merger. Further steps are now being taken to ensure that the potential transaction is achievable. The Company expects to be able to provide more details before the annual general meeting on May 7, 2024.
Read more: InDex discontinues development of cobitolimod and provides future update
The decision on how to proceed will be subject to shareholder approval at a later extraordinary general meeting.
Photo of Jenny Sundqvist, CEO Index Pharmaceuticals, who will leave the company per September 26, 2024
